Cue Biopharma (CUE) Short-Term Debt repayments (2023 - 2025)
Cue Biopharma (CUE) has disclosed Short-Term Debt repayments for 3 consecutive years, with -$1.5 million as the latest value for Q4 2025.
- Quarterly Short-Term Debt repayments fell 50.15% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.5 million through Dec 2025, down 12.53% year-over-year, with the annual reading at -$4.5 million for FY2025, 12.53% down from the prior year.
- Short-Term Debt repayments hit -$1.5 million in Q4 2025 for Cue Biopharma, down from -$1.0 million in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of -$999000.0 in Q4 2024 to a low of -$1.5 million in Q4 2025.
- Historically, Short-Term Debt repayments has averaged -$1.0 million across 3 years, with a median of -$1.0 million in 2023.
- Biggest five-year swings in Short-Term Debt repayments: grew 0.1% in 2024 and later plummeted 50.15% in 2025.
- Year by year, Short-Term Debt repayments stood at -$1.0 million in 2023, then increased by 0.1% to -$999000.0 in 2024, then crashed by 50.15% to -$1.5 million in 2025.
- Business Quant data shows Short-Term Debt repayments for CUE at -$1.5 million in Q4 2025, -$1.0 million in Q3 2025, and -$1.0 million in Q2 2025.